GREENWICH, Conn., Aug. 28, 2023 /PRNewswire/ -- Vesselon Inc. introduced the first on-site co-formulation platform that can enhance cellular uptake and response to therapy, without altering the active drug in any way. Compared to traditional administration methods, Vesselon drugs penetrate targeted cells more effectively and improve a drug's bioavailability by multiple fold.
GREENWICH, Conn., May 22, 2023 /PRNewswire/ -- In a major development, Vesselon has discovered how to protect a superior method of delivering drugs shown to be effective in more than 1,700 independent preclinical and clinician-sponsored human trials. Despite compelling evidence that the method improves the Therapeutic Index of numerous drugs in many indications, its promise has been ignored by the pharmaceutical industry because it has not been patentable, until now.